Imnovid: immunomodulator for multiple myeloma

Imnovid (pomalidomide) is indicated in combination with dexamethasone for relapsed and refractory multiple myeloma that has progressed in patients who have received at least two prior therapies, including lenalidomide and bortezomib.

by
 Imnovid is given as 4mg once daily on days 1—21 of repeated 28-day cycles, with the dose adjusted according to response
Imnovid is given as 4mg once daily on days 1—21 of repeated 28-day cycles, with the dose adjusted according to response

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package